The CYP2C9 genotype predicts the blood pressure response to irbesartan: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial

Journal of Hypertension

Volumn 20, Issue 10, 2002, Pages 2089-2093

  Hallberg, Pär ^a   Karlsson, Julia ^a   Kurland, Lisa ^a   Lind, Lars ^a   Kahan, Thomas ^a   Malmqvist, Karin ^a   Peter Ohman K ^a   Nyström, Fredrik ^a   Melhus, Håkan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin; Atenolol; Blood pressure; CYP2C9; Gene; Human; Hypertension; Irbesartan; Minisequencing; Pharmacogenetics

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2C9; IRBESARTAN; LOSARTAN; PHENYTOIN; WARFARIN; BIPHENYL DERIVATIVE; CYP2C9 PROTEIN, HUMAN; TETRAZOLE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG METABOLISM; DRUG RESPONSE; ESSENTIAL HYPERTENSION; FEMALE; GENE EXPRESSION; GENE SEQUENCE; GENOTYPE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WILD TYPE; AGED; COMPARATIVE STUDY; DIASTOLE; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; GENETICS; HYPERTENSION; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; SYSTOLE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; ATENOLOL; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DIASTOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS; SWEDEN; SYSTOLE; TETRAZOLES; TREATMENT OUTCOME;

EID: 0036808254     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200210000-00030     Document Type: Article

References (17)

1. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7:361-367.
2. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719.
3. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: Baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996; 333:447-458.
4. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 1997; 7:203-210.
5. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4:39-42.
6. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjöqvist F. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999; 254:628-631.
7. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96:1816-1819.
8. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52:349-355.
9. Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther 2001; 70:391-394.
10. van der Weide J, Steijns LS, van Weelden MJ, de Haan K. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11:287-291.
11. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000; 56:135-140.
12. Bourrie M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27:288-296.
13. Yasar U, Tybring G, Hidestrand M, Oscarson M, Ingelman-Sundberg M, Dahl ML, et al. Role of CYP2C9 polymorphism in losartan oxidation. Drug Metab Dispos 2001; 29:1051-1056.
14. Syvänen AC. From gels to chips: 'Minisequencing' primer extension for analysis of point mutations and single nucleotide polymorphisms. Hum Mutat 1999; 13:1-10.
15. Suomalainen A, Syvänen AC. Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing. Mol Biotechnol 2000; 15:123-131.
16. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176.
17. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6:429-439.